Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion type Assertion NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_head.
- NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_provenance.
- NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion evidence source_evidence_literature NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_provenance.
- NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion SIO_000772 9676019 NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_provenance.
- NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion wasDerivedFrom befree-2016 NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_provenance.
- NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion wasGeneratedBy ECO_0000203 NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_provenance.